Bilastuff DX Syrup is an advanced, triple-action formulation designed for the comprehensive relief of symptoms associated with the common cold, flu, and allergic rhinitis. Each 5ml dose provides Dextromethorphan HCl (10mg), a potent cough suppressant for dry cough; Bilastine (3.3mg), a modern, non-sedating antihistamine for allergy symptoms like sneezing and watery eyes; and Phenylephrine (5mg), a reliable decongestant for nasal and sinus congestion. This synergistic blend targets the three most bothersome symptoms of respiratory distress, offering patients fast-acting and long-lasting comfort. Furthermore, the crucial Sugar Free formulation expands the market appeal, making it a safe and preferred choice for diabetic and calorie-conscious consumers.
The market for cough, cold, and anti-allergic preparations is one of the largest and most consistently growing segments in the Indian pharmaceutical industry, driven by environmental factors, pollution, and the high prevalence of seasonal allergies. Products that offer effective, multi-symptom relief with modern, non-sedating antihistamines like Bilastine hold a significant competitive edge and command strong brand loyalty. This makes Bilastuff DX Syrup a high-demand, high-turnover product that is strategically positioned to capture market share, ensuring stable and substantial revenue for our franchise partners.
We offer an exceptional PCD Pharma Franchise opportunity for Bilastuff DX Syrup. Our product is manufactured in a WHO-GMP certified facility, guaranteeing the highest standards of quality and efficacy. We back our partners with a compelling business package, including exclusive monopoly rights in your designated territory to eliminate market competition. You receive complete marketing and promotional support, including visual aids and product samples, to successfully engage healthcare practitioners. By investing in the Bilastuff DX franchise, you secure a partnership committed to your growth, ensuring reliable supply, superior product quality, and the tools needed to build a highly profitable and sustainable business in the respiratory and anti-allergy segment.